Figure S6 from A RAS(ON) Multi-Selective Inhibitor Combination Therapy Triggers Long-term Tumor Control through Senescence-Associated Tumor-Immune Equilibrium in Pancreatic Ductal Adenocarcinoma

Key Points

• Combination therapy with RAS(ON) inhibitors effectively leads to long-term tumor control in pancreatic ductal adenocarcinoma.
• Transcriptional changes in immune cells are significant following RAS(ON) inhibitor-based treatments.
• The approach involves understanding the tumor-immune equilibrium facilitated by senescence in tumor cells.
• This research supports the potential of targeted inhibitors in managing aggressive cancers like pancreatic ductal adenocarcinoma.